Bayer's Analyst Targets Stretch to a 16-Euro Gulf as the September Court Date Becomes the Deciding Factor
Published on 08/17/2026 at 02:42 | Redaktion boerse-global.de
The gap between Wall Street's most bullish and most cautious calls on Bayer has widened into a chasm that leaves investors with a stark choice: trust the balance-sheet repair or fear the legal overhang. With price targets ranging from 46 to 62 euros, the spread now exceeds 16 euros — one of the widest valuation divides the Leverkusen-based conglomerate has seen in recent memory.
The stock itself closed Friday at 47.90 euros, hovering far closer to the skeptical end of that spectrum than to the optimists' projections. The session brought a modest 0.4 percent decline, and over the past week the shares have shed 2.5 percent. On a monthly basis, the move is nearly flat at minus 0.3 percent. Yet those short-term wobbles obscure a remarkable longer-term run: the equity has climbed 29 percent since the start of the year and an eye-catching 72 percent over the trailing twelve months.
A House Divided
The bull camp has been busy since Bayer reported its second-quarter numbers on August 5. JPMorgan Chase lifted its target from 50 to 61 euros while reaffirming an "Overweight" rating. UBS Group followed suit, raising its objective from 52 to 62 euros with a "Buy" recommendation. Deutsche Bank Research kept its own "Buy" stance and a 60-euro target. All three assessments landed on the same day, immediately after the earnings release.
Jefferies, however, has refused to budge. The firm maintained its "Hold" rating and left its price target untouched at 46 euros in a note dated August 10 — a full week after the optimists weighed in. That places the cautious call roughly 15 to 16 euros below the more enthusiastic forecasts, making Jefferies one of the most conservative voices in the coverage universe.
What's Driving the Optimism
The upbeat revisions trace back to an operating performance that beat expectations on multiple fronts. Bayer reported second-quarter adjusted operating profit of 2.14 billion euros on revenue of 10.87 billion euros, comfortably surpassing the average analyst forecast of 1.94 billion euros in EBITDA. Revenue growth came in at 2.2 percent, and the company swung back to profitability after a loss of 199 million euros in the year-earlier quarter.
Should investors sell immediately? Or is it worth buying Bayer?
The Crop Science division benefited from solid agricultural demand, though the pharma segment remained a drag. Management confirmed its full-year guidance and nudged the currency-adjusted revenue corridor slightly higher.
Perhaps more importantly for the bulls, Bayer trimmed its 2026 net debt forecast to a range of 29 to 30 billion euros, down from a prior projection of 32 to 33 billion euros. The improvement is largely attributable to the planned sale of a minority stake in Apollo, valued at 3 billion euros. A leaner balance sheet, the argument goes, gives management more breathing room even if the glyphosate settlement ultimately proves costlier than anticipated.
The Legal Cloud That Won't Lift
That settlement remains the crux of the disagreement. The proposed 7.25 billion US-dollar class-action agreement in Missouri is still awaiting final approval, and the hearing has been pushed back to September 14, 2026 — a three-week delay requested by Bayer itself. Until that date, investors are left to weigh how durable the deal actually is.
For the skeptics at Jefferies, the unresolved glyphosate litigation justifies a more conservative valuation despite the operational progress. The company's solid quarter, in their view, does not offset the legal uncertainty that has dogged the stock for years.
The share price, meanwhile, continues to trade above its 50-day moving average of 45.51 euros — a margin of roughly 5.2 percent — but has failed to break decisively toward either analyst camp's territory. The stock sits in a no-man's-land where the operational recovery is acknowledged but the legal risks keep a lid on enthusiasm.
For investors, the wide target range underscores a simple reality: Bayer's valuation is being driven less by quarterly fundamentals and more by the outcome of a courtroom calendar. The September 14 hearing should go a long way toward determining which side of the analyst divide has read the situation correctly.
Ad
Bayer Stock: New Analysis - 17 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
